Evidence map›Paper›PMID 35289714›Full record

ArticleHuman vaccines & immunotherapeutics2022

A serological investigation in Southern Italy: was SARS-CoV-2 circulating in late 2019?

Claudia Maria Trombetta, Serena Marchi, Simonetta Viviani, Alessandro Manenti, Elisa Casa, Francesca Dapporto, Edmond J Remarque, Valentina Bollati, Ilaria Manini, Giacomo Lazzeri and 1 more

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Claudia Maria TrombettaDepartment of Molecular and Developmental Medicine, University of Siena, Siena, Italy.ORCID 0000-0001-7229-9919
Serena MarchiDepartment of Molecular and Developmental Medicine, University of Siena, Siena, Italy.ORCID 0000-0002-6817-2461
Simonetta VivianiDepartment of Molecular and Developmental Medicine, University of Siena, Siena, Italy.ORCID 0000-0002-3652-5082
Alessandro ManentiVisMederi srl, Siena, Italy.ORCID 0000-0002-4027-7296
Elisa CasaVisMederi Research srl, Siena, Italy.
Francesca DapportoVisMederi Research srl, Siena, Italy.
Edmond J RemarqueDepartment of Virology, Biomedical Primate Research Centre, Rijswijk, The Netherlands.ORCID 0000-0002-5412-6958
Valentina BollatiDepartment of Clinical Sciences and Community Health, University of Milan, Milan, Italy.ORCID 0000-0002-0370-9598
Ilaria ManiniDepartment of Molecular and Developmental Medicine, University of Siena, Siena, Italy.ORCID 0000-0002-5877-3095
Giacomo LazzeriDepartment of Molecular and Developmental Medicine, University of Siena, Siena, Italy.ORCID 0000-0002-9095-7652
Emanuele MontomoliDepartment of Molecular and Developmental Medicine, University of Siena, Siena, Italy.ORCID 0000-0001-7595-4974

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In March 2020, the first pandemic caused by a coronavirus was declared by the World Health Organization. Italy was one of the first and most severely affected countries, particularly the northern part of the country. The latest evidence suggests that the virus could have been circulating, at least in Italy, before the first autochthonous SARS-COV-2 case was detected in February 2020. The present study aimed to investigate the presence of antibodies against SARS-CoV-2 in human serum samples collected in the last months of 2019 (September-December) in the Apulia region, Southern Italy. Eight of 455 samples tested proved positive on in-house receptor-binding-domain-based ELISA. Given the month of collection of the positive samples, these findings may indicate early circulation of SARS-CoV-2 in Apulia region in the autumn of 2019. However, it cannot be completely ruled out that the observed sero-reactivity could be an unknown antigen specificity in another virus to which subjects were exposed containing an epitope adventitiously cross-reactive with an epitope of SARS-CoV-2.

Indexed as

COVID-19SARS-CoV-2Antibodies, ViralEpitopesHumansItalyPandemicsAntibodies, ViralEpitopes2019antibodiesItalySARS-CoV-2

Identifiers

PMID35289714
PMCPMC8935457

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.